Meanwhile, BMO Capital Markets downgraded its Novo Nordisk ADR [NVO] rating to a Market perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Kepler’s analysts, who increased its forecast for the stock in mid March from “a Hold” to “a Buy”. Stifel also remained covering NVO and has decreased its forecast on March 03, 2025 with a “Hold” recommendation from previously “Buy” rating. Morgan Stanley started covering the stock on February 12, 2025. It rated NVO as “an Equal-weight”.
Price Performance Review of NVO
On Friday, Novo Nordisk ADR [NYSE:NVO] saw its stock jump 1.42% to $65.77. Over the last five days, the stock has lost -5.00%. Novo Nordisk ADR shares have fallen nearly -23.54% since the year began. Nevertheless, the stocks have fallen -48.33% over the past one year. While a 52-week high of $148.15 was reached on 02/25/25, a 52-week low of $57.00 was recorded on 04/21/25. SMA at 50 days reached $70.89, while 200 days put it at $99.94.
Levels Of Support And Resistance For NVO Stock
The 24-hour chart illustrates a support level at 65.09, which if violated will result in even more drops to 64.42. On the upside, there is a resistance level at 66.94. A further resistance level may holdings at 68.12. The Relative Strength Index (RSI) on the 14-day chart is 48.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.16, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 37.39%. Stochastics %K at 68.56% indicates the stock is a holding.
